newsfilter
← Latest News
GlobeNewswire·

Talaris Therapeutics Provides Update on FREEDOM-1 Phase 3 Clinical Trial

BOSTON and LOUISVILLE, Ky., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of